Objective To analyze the efficacy of gamma globulin combined with recombinant human interferon α1b in the treatment of viral encephalitis (VE) in children and its influence on serum C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels. Methods The clinical data of 98 children with VE from January 2022 to December 2023 were retrospectively collected. According to different treatment methods, they were divided into interferon group (51 cases) and combined group (47 cases). The interferon group was given conventional treatments such as antiviral therapy and intracranial pressure reduction and recombinant human interferon α1b treatment, while the combined group was combined with gamma globulin on the basis of the interferon group. The disappearance times of clinical symptoms and signs in the two groups were recorded. The immune function T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+), immunoglobulin[IgE, IgG], inflammatory factors (CRP, IL-6, TNF-α), and brain injury-related factors [Tau protein, nerve growth factor (NGF), neuron-specific enolase (NSE)] were compared between the two groups before treatment and after 5 days of treatment, and the safety of medication was evaluated. Results The time to defervescence, disappearance of headache, dizziness, vomiting, seizures, and meningeal irritation signs in the combined group was shorter than that in the interferon group. After 5 days of treatment, the levels of CD4+, CD4+/CD8+ ratio, IgE, and IgG in the combined group were higher than those in the interferon group, while the serum levels of CRP, IL-6, TNF-α, Tau protein, NGF, and NSE were lower than those in the interferon group, and the differences were statistically significant. There was no significant difference in the incidence of adverse drug reactions between the two groups. Conclusion Gamma globulin combined with recombinant human interferon α1b in the treatment of VE in children can improve the immune function, relieve the inflammatory response and brain injury, and promote the reliefs of clinical symptoms and signs, and it has good safety.
Key words
viral encephalitis /
children /
gamma globulin /
recombinant human interferon α1b /
immune function /
inflammation
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] VOVA JA, HOWARTH RA.Evaluation, treatment, and outcomes of viral and autoimmune encephalitis in children[J]. Pediatr Clin North Am, 2023, 70(3): 429-444.
[2] XU XQ, XU T, JI W, et al.Herpes simplex virus 1-induced ferroptosis contributes to viral encephalitis[J]. mBio, 2023, 14(1): e0237022.
[3] GERVAIS A, ROVIDA F, AVANZINI MA, et al.Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ～40% of patients[J]. J Exp Med, 2023, 220(9): e20230661.
[4] WANG Z, AMAYA M, ADDETIA A, et al.Architecture and antigenicity of the Nipah virus attachment glycoprotein[J]. Science, 2022, 375(6587): 1373-1378.
[5] 胡亚美, 江载芳. 诸福棠实用儿科学[M].8版. 北京: 人民卫生出版社, 2015: 854-858.
[6] SONNEVILLE R, JAQUET P, VELLIEUX G, et al.Intensive care management of patients with viral encephalitis[J]. Rev Neurol (Paris), 2022, 178(1-2): 48-56.
[7] NG WM, FEDOSYUK S, ENGLISH S, et al. Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies[J]. Cell Host Microbe, 2022, 30(9): 1219-1230. e7.
[8] AKSAMIT AJ JR.Treatment of viral encephalitis[J]. Neurol Clin, 2021, 39(1): 197-207.
[9] 黄沛. 儿童重型病毒性脑炎药物治疗进展[J]. 妇儿健康导刊, 2025, 4(16): 26-29.
[10] 张丽华. 重组人干扰素α-1b联合大剂量丙种球蛋白治疗HFMD并病毒性脑炎患儿的效果[J]. 中外医学研究, 2020, 18(34): 67-69.
[11] SHI Q, LIU L, ZHANG W, et al.Interferon-α1b for the treatment of metastatic melanoma: results of a retrospective study[J]. Anticancer Drugs, 2021, 32(10): 1105-1110.
[12] WAGNER JN, LEIBETSEDER A, TROESCHER A, et al.Efficacy and safety of intravenous immunoglobulins for the treatment of viral encephalitis: a systematic literature review[J]. J Neurol, 2022, 269(2): 712-724.
[13] 蔡宇哲, 潘旭. 氢化可的松联合丙种球蛋白治疗小儿病毒性脑炎的效果分析[J]. 淮海医药, 2025, 43(06): 632-635.
[14] WILCOX DR, COLLENS SI, SOLOMON IH, et al.Eastern equine encephalitis and use of IV immunoglobulin therapy and high-dose steroids[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 8(1): e917.
[15] GIOVANNINI J, SMERALDA W, JOUANNE M, et al.Tau protein aggregation: Key features to improve drug discovery screening[J]. Drug Discov Today, 2022, 27(5): 1284-1297.
[16] LI B, NING B, YANG F, et al.Nerve growth factor promotes retinal neurovascular unit repair: a review[J]. Curr Eye Res, 2022, 47(8): 1095-1105.
[17] NÜBEL J, BUHRE C, HOFFMEISTER M, et al. Association between neuron-specific enolase, memory function, and postoperative delirium after transfemoral aortic valve replacement[J]. J Cardiovasc Dev Dis, 2023, 10(11): e10110441.
[18] BHARUCHA T, AYHAN N, PASTORINO B, et al.Immunoglobulin M seroneutralization for improved confirmation of Japanese encephalitis virus infection in a flavivirus-endemic area[J]. Trans R Soc Trop Med Hyg, 2022, 116(11): 1032-1042.
[19] MARRIAGA-NÚÑEZ B, ARELLANO-VALDEZ A, PAZ JPA, et al. Immunoglobulin-resistant Kawasaki disease[J]. Bol Med Hosp Infant Mex, 2023, 80(4): 260-264.
[20] 申昆玲, 尚云晓, 张国成, 等. α干扰素在儿科临床合理应用专家共识[J]. 中华实用儿科临床杂志, 2018, 33(17): 1301-1308.
[21] 吴华峰, 万志军, 刘立亚, 等. 丙种球蛋白与干扰素治疗手足口病并发病毒性脑炎的临床效果比较[J]. 中国基层医药, 2014, 21(20): 3127-3128.
[22] 李晓娟, 李晓丽, 陈珊珊. 重组人干扰素α-2b联合常规抗病毒治疗病毒性脑炎患儿的疗效评价[J]. 国际医药卫生导报, 2020, 26(07): 913-916.
[23] 朱华珍, 林香媛. 静脉滴注人血丙种球蛋白应用在新生儿溶血性黄疸治疗中的效果探讨[J]. 基层医学论坛, 2025, 29(30): 99-101.
[24] 王玲玲, 关歌, 李文豪. 丙种球蛋白剂量对儿童免疫性血小板减少症疗效影响[J]. 中国小儿血液与肿瘤杂志, 2025, 30(05): 357-360.
[25] 王金雪, 王瑞晔, 邓三亮, 等. 丙种球蛋白治疗儿童传染性单核细胞增多症的回顾性分析[J]. 黑龙江医药科学, 2025, 48(10): 191-193.
PDF(1736 KB)
